How One AI Platform Is Cutting Years Off Drug Discovery - Yann Gaston-Mathé

95% of our viewers aren't subscribed. If you're watching and not yet subscribed, please subscribe to the channel so you don't miss future episodes.What does it take to improve a drug discovery success rate of less than 1%? In this episode, Yann Gaston-Mathé explains how AI, robotics, and laboratory automation are being combined to accelerate the development of new medicines and tackle some of the industry's most challenging drug targets.This week on Leading Beyond The Lab, Lawrence Rose sat down with Yann Gaston-Mathé, CEO and Co-Founder of Iktos, with more than 20 years of experience spanning pharmaceutical R&D, data science, IT, strategic consulting, entrepreneurship, and AI-driven drug discovery.In this episode, Yann Gaston-Mathé covers:• How Iktos is tackling the inefficiency of small molecule drug discovery and why overall success rates remain below 1% • What differentiates Iktos from other AI drug discovery companies by combining generative AI with laboratory automation and robotic synthesis• The journey from large pharmaceutical organisations into entrepreneurship and the founding story behind Iktos in 2016 • How AI, predictive modelling, robotics and iterative design-make-test cycles are transforming drug discovery workflows • Why the next frontier for AI in healthcare is improving clinical success rates and reducing development timelines that currently take 8 to 10 years Yann provides a practical perspective on where AI is creating real value in drug discovery, the importance of combining software with experimental science, and why human expertise remains central to the future of pharmaceutical innovation.If you're interested in AI, biotechnology, drug discovery, pharmaceutical R&D, laboratory automation, or the future of healthcare innovation, this episode offers valuable insight from someone building and deploying these technologies today.Throughout the conversation, Lawrence and Yann discuss the evolution of @Iktos, collaborations across the pharmaceutical industry, and lessons learned from working with global pharmaceutical and biotechnology partners.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ngInstagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qrTikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575Website: https://arto-talent.com/Youtube: https://www.youtube.com/@artotalentYann Gaston-MathéLinkedIn: https://www.linkedin.com/in/yann-gaston-mathe-9850a21/Lawrence RoseLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Introduction and episode highlights01:37 Welcome to Leading Beyond The Lab07:19 The founding story behind Iktos08:05 Career journey through pharma, consulting, IT and data science10:09 Leaving large pharmaceutical companies for entrepreneurship11:10 How the Iktos platform works16:41 Automation and scaling medicinal chemistry workflows22:03 Measuring impact, speed and efficiency in drug discovery26:19 Competition within AI drug discovery27:30 The future of AI in pharmaceutical R&D29:35 Building strategic pharmaceutical partnerships30:52 Evaluating new collaboration opportunities32:18 Working across global cultures and organisations33:35 Creating value through partnerships35:45 Scaling resources and managing growth41:09 Challenges in building automated laboratory infrastructure42:12 Will AI replace chemists?45:29 Will AI ever fully replace human scientists?47:59 What continues to motivate Yann Gaston-Mathé49:24 Advice for the next generation of scientists50:38 Science, technology and the future workforce51:06 Closing remarks#LeadingBeyondTheLab #ARTOTalent #DrugDiscovery #ArtificialIntelligence #Biotech #Pharmaceuticals #LifeSciences #LaboratoryAutomation #MachineLearning #HealthcareInnovation #DrugDevelopment #GenerativeAI Hosted on Acast. See acast.com/privacy for more information.